Rajagopal Ramesh, PhD

 Rajagopal Ramesh, PhD

Stephenson Cancer Center 
Stanton L. Young Biomedical Research Center
Suite # 1403
University of Oklahoma Health Sciences Center
975 N.E., 10th Street
Oklahoma City, OK 73104

PHONE: 405-271-6101 Ext: 52501

E-MAIL: rajagopal-ramesh@ouhsc.edu 


Jim and Christy Everest Endowed Chair in Cancer Developmental Therapeutics
Professor of Pathology
Director, Experimental Therapeutics and Translational Cancer Medicine
Chair, Fellowship Training and Mentoring Program
Member, OU Cancer Institute


B.Sc. - Biology, Osmania University
Hyderabad, India, 1985

M.Sc - Microbiology
Osmania University
Hyderabad, India, 1987

Annamalai Univeristy
Tamil Nadu, India, 1992

Ph.D. - Molecular Biology
All India Institute of Medical Sciences (AIIMS)
New Delhi, India, 1994

Post-Doctoral Fellow
Tulane University Medical Center, 
New Orleans, LA, 1997

Research Interests/Sub-Specialty

Studies in my laboratory are mainly focused on novel gene-based therapeutics using viral and non-viral vectors with emphasis on translational cancer research. There are two major research areas that are actively being pursued in the laboratory. The first research area is the development and testing of non-viral and nanoparticle-based gene delivery for cancer treatment, and the second research area is studying the antitumor and anti-angiogenic properties of IL-24. Our findings have lead to Phase I clinical trials for treatment of solid tumors.

Memberships & Certifications

Member, American Association for Cancer Research (AACR), 1994-present
Member, American Society of Cell and Gene Therapy (ASCGT), 1995-present
Member, American Society of Clinical Oncology (ASCO), 2007, present
NCI Career Development study section member, 2006-present
Co-Chair, Suicide gene therapy and apoptosis section, American Society of Cell and Gene Therapy (ASCGT), 2008


  1. Srivastava A, Filant J, Moxley KM, Sood A, McMeekin S, Ramesh R. Exosomes: A role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment. Curr Gene Ther. Epub ahead of print 2014 Dec 23. doi: 10.2174/1566523214666141224100612. PMID: 25537774. (Print issue: 2015, Vol 15.)  

  2. Panneerselvam J, Shanker M, Jin J, Branch CD, Muralidharan R, Zhao DY, Chada S, Munshi A, Ramesh R. Phosphorylation of interleukin (IL)-24 is required for its anticancer activity. Oncotarget. 2015 May 18;6(18):16271-16286. PMID: 26009991.

  3. Ha JH, Gomathinayagam R, Yan M, Jayaraman M, Ramesh R, Dhanasekaran DN. Determinant role for the gep oncogenes, Gα12/13, in ovarian cancer cell proliferation and xenograft tumor growth. Genes Cancer. 2015; Advance Publication, 2015 Aug 3.  

  4. Al Mubarak ZH, Ramesh R, Liu L, Krishnan S. Surface plasmon resonance imaging of gold-small molecule interactions is influenced by refractive index and chemical structures. J Colloid Interface Sci. Epub ahead of print 25 Aug 2015;460:209-213. doi: 10.1016/j.jcis.2015.08.059. PMID: 26321574.  

  5. Klionsky DJ, Abdelmoshen K, Abe A, Abdedin MG, Hagai A, Arozena AA, Adachi H, Adams CM, Adams PD, Ramesh R, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. (3rd Edition) Autophagy. 12(1):1-222, ePub 21 Jan 2016. doi:10.1080/15548627.2015.1100356. PMID: 26799652

  6. Yang J, Hannafon BN, Zhang RR, Fung KM, Ding WQ. Docosahexaenoic acid and disulfiram act in concert to kill cancer cells: a mutual enhancement of their anticancer actions. Oncotarget. 2017 Jan 17. doi: 10.18632/oncotarget.14702. [Epub ahead of print] PMID: 28107189

  7. Amreddy N, Babu A, Muralidharan R, Munshi A, Ramesh R. Polymeric nanoparticle-mediated gene delivery for lung cancer treatment. Top Curr Chem (J). 2017 Apr;375(2):35. doi: 10.1007/s41061-017-0128-5 (Epub ahead of print) PMID: 28290155  

  8. Babu A, Ramesh R. Multifaceted applications of chitosan in cancer drug delivery and therapy. Mar Drugs. 2017 Mar 27;15(4). pii: E96. doi: 10.3390/md15040096. PMID: 28346381

  9. Griffith J, Andrade D, Mehta M, Berry W, Benbrook DM, Aravindan N, Herman TS, Ramesh R, Munshi A. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol Rep. 2017 Feb 28. doi: 10.3892/or.2017.5478 (Epub ahead of print) PMID: 28260023

  10. Babu A, Munshi A, Ramesh R. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems. Drug Dev Ind Pharm. 2017 May 19:1-11. doi: 10.1080/03639045.2017.1313861. [Epub ahead of print]. PMID: 28523942